

## **MOUNTAIN VIEW PHARMACEUTICALS GRANTS WORLDWIDE LICENSE FOR A LONG-ACTING PROTEIN**

Menlo Park, CA -- June 29, 2005 -- Mountain View Pharmaceuticals, Inc. ("MVP"), announced today the execution of an exclusive worldwide Research, License and Commercialization Agreement with an undisclosed major multinational pharmaceutical company, for a long-acting polymer conjugate of a protein being developed as therapy for a serious and poorly managed disease that afflicts a large patient population.

MVP will receive a series of license and milestone payments, research and development support and royalties on sales once the long-acting polymer conjugate is commercialized.

The "Top-20" global pharmaceutical company partnering with MVP currently markets this therapeutic protein in every major world market. The projected worldwide market for the long-acting polymer conjugate of this protein exceeds \$1 billion.

"We are very encouraged to see MVP's Rational PEGylation<sup>SM</sup> technology adopted for a third major therapeutic protein, only a few months after the Company executed an exclusive, worldwide license agreement for its PEG-interferon-beta with Schering AG, Germany," said Jean M. Bellin, Chief Executive Officer of MVP.

"We are especially pleased that this Agreement involves MVP's proprietary PharmaPEG<sup>®</sup> technology, which can produce conjugates with unusually low immunologic reactivity compared with even the most advanced PEGylation technology used by others," added Dr. Merry R. Sherman, President of MVP.

### About Mountain View Pharmaceuticals, Inc. (MVP)

Founded in November 1995, MVP is a private company engaged in the research and development of long-acting polymer conjugates of therapeutic proteins.

MVP's proprietary technology, referred to as Rational PEGylation<sup>SM</sup>, is a next-generation strategy for attaching poly(ethylene glycol) or PEG to therapeutic proteins to enhance their safety, efficacy and duration of action.

Rational PEGylation<sup>SM</sup> involves the selective coupling of PEG to sites that are remote from the functional regions of proteins. This strategy provides an improved yield of nearly homogeneous preparations that function much more effectively than the products of earlier PEGylation technologies.

MVP's combinatorial approach and unique expertise enable the rapid and cost-effective optimization of the chemistry of attachment, as well as the size, structure and the number of strands of PEG. MVP's novel PEGylation technology is broadly applicable to enzymes, therapeutic viruses, polypeptide hormones, growth factors and cytokines, such as interferons and interleukins.

In addition to the site-selective coupling of PEG, MVP has invented a proprietary polymer with an improved immunologic profile, trademarked PharmaPEG<sup>®</sup>.

MVP's technology is protected by a strong intellectual property estate of issued US patents, corresponding issued patents in Europe and other countries, and six families of pending patent applications in the US and up to 60 other countries. Several of MVP's issued patents relate to its most advanced product, for which a Phase 2 clinical trial has been completed successfully by its licensee.

CONTACT: Mark G. P. Saifer, Ph.D.  
saifer@mvpharm.com  
Mountain View Pharmaceuticals, Inc.  
3475-S Edison Way  
Menlo Park, California 94025-1821  
Phone: 650-365-5515 x 228  
Fax: 650-365-5525  
[www.mvpharm.com](http://www.mvpharm.com)